SCHEMBL4222620

SCHEMBL4222620

Cc1cccc(Nc2cc(-c3ccccc3)ccc2C(=O)O)c1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 6/20 0.66
AKR1C2 P52895 6/20 0.66
MCL1 Q07820 2/20 0.60
ACLY P53396 4/20 0.58
XDH P47989 1/20 0.55
SLC22A12 Q96S37 1/20 0.55
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MAPT P10636 1/20 0.53
ALDH1A1 P00352 1/20 0.52
HCAR2 Q8TDS4 1/20 0.52
SIRT2 Q8IXJ6 1/20 0.51
SIRT1 Q96EB6 1/20 0.51
AURKA O14965 1/20 0.51
MAPK8 P45983 1/20 0.51
AURKB Q96GD4 1/20 0.51
NPSR1 Q6W5P4 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4223666 0.90 SIRT2 (0.61) AKR1C3AKR1C2ACLYMAPTSIRT2
SCHEMBL9595564 0.87 AKR1C3 (0.74) AKR1C3AKR1C2XDHSLC22A12MEN1
SCHEMBL4223119 0.87 AKR1C3 (0.60) AKR1C3AKR1C2MCL1ACLYMAPT
SCHEMBL4210450 0.86 AKR1C3 (0.62) AKR1C3AKR1C2MCL1ACLYXDH
SCHEMBL4212934 0.84 SIRT2 (0.52) AKR1C3AKR1C2ACLYHCAR2SIRT2
SCHEMBL10144302 0.84 AKR1C3 (0.68) AKR1C3AKR1C2MEN1KMT2AMAPT
SCHEMBL29391834 0.84 AKR1C3 (0.68) AKR1C3AKR1C2MEN1KMT2AMAPT
SCHEMBL4223069 0.84 MPO (0.61) AKR1C3AKR1C2ACLYMEN1KMT2A
SCHEMBL8390874 0.84 AKR1C3 (0.71) AKR1C3AKR1C2XDHSLC22A12MEN1
SCHEMBL4222990 0.84 ACLY (0.59) AKR1C3AKR1C2MCL1ACLYMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 AKR1C3 105/4885AKR1C2 287/4885MCL1 1183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.